)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Organogenesis
Organogenesis (ORGO) investor relations material
Organogenesis Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Achieved record Q4 and FY 2025 revenue, with Q4 net product revenue of $225.1 million (up 78% YoY) and FY 2025 revenue of $563.0 million (up 17% YoY), driven by 83% YoY growth in advanced wound care sales.
Net income rose to $43.7 million in Q4 2025 from $7.7 million in Q4 2024; FY 2025 net income was $37.0 million, up from $0.9 million in FY 2024.
Navigated significant CMS policy changes, shifting reimbursement to PMA products and supporting innovation and higher-value offerings.
Faced market disruption and clinician confusion in early 2026 due to CMS commentary and withdrawal of LCD coverage, impacting utilization of PMA-approved products.
Advanced strategic initiatives, including a new manufacturing and R&D center and progress on the ReNu program targeting knee osteoarthritis.
Financial highlights
Q4 2025 net product revenue was $225.1 million, up 78% year-over-year and 50% sequentially; FY 2025 revenue was $563.0 million, up 17% year-over-year.
Advanced wound care revenue reached $217.2 million in Q4 (up 83% YoY); Surgical and Sports Medicine revenue was $7.9 million in Q4 (down 2% YoY).
Gross profit for Q4 was $175.2 million (78% margin), up from 75% last year; FY 2025 gross margin was 76%.
Operating income for Q4 was $63.3 million, up 519% YoY; FY 2025 operating income was $44.7 million, reversing a loss in FY 2024.
Adjusted EBITDA for Q4 was $84.2 million (37% margin), up from $18.2 million last year; FY 2025 adjusted EBITDA was $98.1 million.
Outlook and guidance
FY 2026 net revenue guidance is $350–$420 million, a 25–38% decline from FY 2025, reflecting anticipated short-term disruption from CMS reimbursement changes.
Q1 2026 revenue projected to decline ~50% YoY; first-half revenue expected to decline 30%-35%.
Sequential revenue growth anticipated in Q3 and Q4 2026, with positive adjusted EBITDA and high teens EBITDA margins in Q4.
Management expects normalized annual growth post-2026, with recovery and normalized growth anticipated in 2027.
Primary driver of Q1 2026 revenue decline
Competitive landscape evolution in 2026
Strategy to resolve clinician confusion
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Organogenesis
- Strong product innovation and regulatory adaptation drive growth amid reimbursement shifts.ORGO
2024 Cantor Fitzgerald Global Healthcare Conference3 Feb 2026 - Q2 revenue up 11% to $130.2M, but net loss widened on impairments and write-downs.ORGOQ2 20241 Feb 2026
- Q3 net income rose to $12.3M on 6% revenue growth; 2024 outlook strong despite regulatory risks.ORGOQ3 202414 Jan 2026
- Regulatory changes, new launches, and a robust pipeline position the company for strong future growth.ORGOCantor Global Healthcare Conference 20255 Jan 2026
- Regenerative medicine firm seeks to raise $250M and enable resale of 50M shares by holders.ORGORegistration Filing16 Dec 2025
- Registering 130,000 Series A Preferred and 34.3M Common Shares for resale by private investors.ORGORegistration Filing16 Dec 2025
- Annual meeting to vote on directors, executive pay, major stock issuance, and auditor ratification.ORGOProxy Filing2 Dec 2025
- Key votes on director elections, executive pay, major stock issuance, and auditor ratification.ORGOProxy Filing2 Dec 2025
- Q4 revenue up 27% year-over-year; FY 2025 guidance signals growth despite LCD headwinds.ORGOQ4 20241 Dec 2025
Next Organogenesis earnings date
Q1 20267 May, 2026
Organogenesis
Next Organogenesis earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage